179 related articles for article (PubMed ID: 3163149)
1. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer.
Benini L; Cavallini G; Zordan D; Rizzotti P; Rigo L; Brocco G; Perobelli L; Zanchetta M; Pederzoli P; Scuro LA
Pancreas; 1988; 3(1):61-6. PubMed ID: 3163149
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma.
Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC
Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358
[TBL] [Abstract][Full Text] [Related]
3. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.
Staab HJ; Brümmendorf T; Hornung A; Anderer FA; Kieninger G
Klin Wochenschr; 1985 Feb; 63(3):106-15. PubMed ID: 3856076
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
[TBL] [Abstract][Full Text] [Related]
5. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis.
Del Favero G; Fabris C; Plebani M; Panucci A; Piccoli A; Perobelli L; Pedrazzoli S; Baccaglini U; Burlina A; Naccarato R
Cancer; 1986 Apr; 57(8):1576-9. PubMed ID: 3456255
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.
Steinberg WM; Gelfand R; Anderson KK; Glenn J; Kurtzman SH; Sindelar WF; Toskes PP
Gastroenterology; 1986 Feb; 90(2):343-9. PubMed ID: 2416628
[TBL] [Abstract][Full Text] [Related]
7. [The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis].
Basso D; Fabris C; Del Favero G; Panucci A; Piccoli A; Plebani M; Pedrazzoli S; Baccaglini U; Lise M; Burlina A
Minerva Med; 1986 Apr; 77(16):613-6. PubMed ID: 3458035
[TBL] [Abstract][Full Text] [Related]
8. Tumour markers in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Jalanko H
Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
[TBL] [Abstract][Full Text] [Related]
9. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
12. [CA-19-9, CA50 and CEA in pancreatic and gastrointestinal tumors. Comparative studies].
Dienst C; Clodius T; Oldörp T; Uhlenbruck G; Diehl V
Med Klin (Munich); 1987 Jan; 82(2):45-50. PubMed ID: 3470595
[No Abstract] [Full Text] [Related]
13. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer.
Kiriyama S; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Ono H; Sakai Y
Cancer; 1990 Apr; 65(7):1557-61. PubMed ID: 2311067
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
15. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
Wu JT
Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
[TBL] [Abstract][Full Text] [Related]
16. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive diagnosis of advanced pancreatic cancer by real-time ultrasonography, carcinoembryonic antigen, and carbohydrate antigen 19-9.
Wang TH; Lin JT; Chen DS; Sheu JC; Sung JL
Pancreas; 1986; 1(3):219-23. PubMed ID: 3554223
[TBL] [Abstract][Full Text] [Related]
18. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
19. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
[TBL] [Abstract][Full Text] [Related]
20. [Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis].
Changchine CS; Yung CY; Tzen KY
Changgeng Yi Xue Za Zhi; 1991 Mar; 14(1):32-8. PubMed ID: 2039968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
